Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study aims to assess the impact of IL28B rs8099917 polymorphism on CHC genotype 4 (G4) susceptibility and liver fibrosis progression individually; and in combination with PNPLA3 rs738409.<b>Patients and methods:</b> IL28B rs8099917 and PNPLA3 rs738409 were genotyped in 150 Egyptian CHC patients and 175 healthy controls using real-time PCR.<b>Results:</b> IL28B rs8099917 genotype distribution significantly differs in healthy individuals versus CHC patients (<i>p</i> = .018); and in low versus advanced fibrosis IL28B (<i>p</i> = .013).
|
31793339 |
2019 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, IFNL3 serum levels and the genetic variant known to be associated with liver fibrosis are similarly linked to PF, but not to worsening of skin fibrosis in SSc.
|
31619697 |
2019 |
Fibrosis, Liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interferon-λ3 levels were significantly higher after viral clearance in patients who developed HCC and were associated with a higher potential for hepatocarcinogenesis, such as a higher frequency of non-hypervascular hypointensive nodules (P = 0.046), higher stages of liver fibrosis (P < 0.001), and higher post-treatment levels of Wisteria floribunda agglutinin positive Mac-2 binding protein (P < 0.001) and alanine aminotransferase (P < 0.001).
|
30623518 |
2019 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Data Mining and Machine Learning Algorithms Using IL28B Genotype and Biochemical Markers Best Predicted Advanced Liver Fibrosis in Chronic Hepatitis C.
|
29279441 |
2018 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
In patients who had advanced liver fibrosis but not HCV-1 infection, factors that had significant independent associations with advanced liver fibrosis included age (OR/CI: 1.039/1.016-1.063, P = .001) and platelet count (OR/CI: 0.99/0.986-0.995, P < .001); additionally, IL-28B genetic variants were not associated with liver disease severity.Unfavorable IL-28B genetic variants were associated with advanced liver disease.
|
29517696 |
2018 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A significant correlation between liver fibrosis and IL28B polymorphism emerges.
|
27271956 |
2017 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We assessed HCV RNA, HCV genotype (GT), IL28B GT and liver fibrosis (FibroScan<sup>®</sup> ) in 480 HIV-infected patients with positive HCV antibody in four HIV treatment centres in South-East Asia.
|
27917597 |
2017 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, the role of the IFNL3 polymorphisms in influencing the spontaneous clearance of HCV, the response to interferon and the progression of liver fibrosis, was also demonstrated in patients with thalassemia major infected by genotype 1b.
|
25864220 |
2016 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analysis revealed IL28B rs12979860 CC genotype (OR = 3.12; 95% CI, 1.72-5.67; P < 0.001), hepatitis C virus RNA < 400,000 IU/ml (OR = 2.21; 95% CI, 1.22-3.99, P < 0.05), age < 45 years (OR = 2.03; 95% CI, 1.11-3.68; P < 0.05), and liver fibrosis stage 0-1 (OR = 1.64; 95% CI, 1.01-2.65, P < 0.05) were independent factors for SVR.
|
26339796 |
2015 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To perform a comprehensive study on independent modulators of liver fibrosis progression and determinants of portal pressure considering immune status, insulin resistance (IR), serum 25-hydroxyvitamin D (25(OH)D) levels, genetic variants of patatin-like phospholipase domain-containing protein 3 (PNPLA3) and interleukin 28B (IL28B) in a thoroughly documented cohort of HIV/hepatitis C-coinfected (HIV/HCV) patients.
|
24905495 |
2015 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Silencing of IP10 is positive and independent from IL28B prediction of SVR, which is strongly associated with liver fibrosis in CHC patients.
|
26115415 |
2015 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, in the subset of patients with baseline advanced liver fibrosis (Metavir F3-F4), those with treatment failure experienced less hepatic decompensation events or deaths than untreated patients (19% versus 42%; P=0.005) and this finding was more pronounced in patients harbouring IL28B-CC alleles (15.8% versus 47.4%; P=0.02).
|
25105286 |
2015 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
IFN-λ(3) is a biomarker reflecting the activity and fibrosis of liver disease, but is not correlated with the responsiveness to PEG-IFN-α plus RBV therapy.
|
25501286 |
2015 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Advanced liver fibrosis was neither associated with PNPLA3 (p = 0.253) nor IL28B-genotype (p = 0.628), but with HCV-GT3 (p = 0.003), higher BMI (p = 0.008) and higher age (p = 0.007).
|
26599080 |
2015 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In contrast, the IL28B genotype does not affect disease progression such as hepatic fibrosis.
|
25100136 |
2014 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Advanced liver fibrosis (p = 0.004) and the magnitude of HCV decrease at week 4 (p < 0.001) but not IL28B were associated with non-response.
|
23689988 |
2014 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To establish the role of liver fibrosis as a predictive tool of response to pegylated interferon alpha (Peg-IFN) and ribavirin (RBV) treatment in human immunodeficiency (HIV)/hepatitis C virus (HCV) coinfected patients, in addition to recognized predictive factors (HCV load, HCV genotype, IL-28B polymorphism).
|
25013899 |
2014 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis.
|
24637774 |
2014 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Liver fibrosis has been associated with hepatitis C virus (HCV) genotype and genetic variation near the interleukin 28B (IL28B) gene, but the relative contribution is unknown.
|
25545640 |
2014 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IL28B rs12979860 (IL28B) non-C/C, advanced liver fibrosis and high HCV RNA were considered as established risk factors for treatment failure.
|
24342953 |
2014 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The variables significantly associated with SVR in a multivariate analysis were HCV-genotype (GT) 3 {adjusted odds ratio [aOR] = 7.66 [95% of confidence interval (95% CI): 3.96 to 14.81] P < 0.001}, HCV-viremia <500,000 IU/mL [aOR = 2.20 (95% CI: 1.16 to 4.15] P = 0.015), no/mild liver fibrosis (F < 2) [aOR = 1.92 (95% CI: 1.08 to 3.42) P = 0.026], IL28B rs12980275 AA genotype [aOR = 2.70 (95% CI: 1.54 to 4.71) P < 0.001], and PPARγ2 rs1801282 CG/GG genotype [aOR = 2.93 (95% CI: 1.27 to 6.72) P = 0.011].
|
25072612 |
2014 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Additionally the presence of the otherwise favorable IL28B genetic variants in the context of HCV genotype 3 infection reportedly entail more pronounced liver fibrosis and steatosis.
|
24244641 |
2013 |
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Logistic regression analysis adjusting by [Age], [Sex], [HCV viral genotype], [HCV viral load], [HIV viral load], and [CD4 T cells levels] revealed the IL-28B rs12979860 (CT/TT) genotype as a protective factor against alanine aminotransferase (ALT) levels (>100 IU/L), aspartate aminotransferase (AST) levels (>75 IU/L), and AST-to-platelet ratio index (APRI) score for liver fibrosis (>1.5) [OR, (95% CI), p]: ALT [0.026 (0.001-0.576) 0.021]; AST [0.001 (0.000-0.297) 0.019]; APRI [0.031 (0.002-0.41) 0.008].
|
23030669 |
2013 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interferon (IFN) preactivation, interleukin-28B (IL28B) alleles, and liver fibrosis act as predictors of response to antiviral therapy against hepatitis C. We aimed to verify if blood IFN concentration, a putative biomarker of interferon preactivation, might depend on carriage of a given IL28B genotype and/or advanced hepatic fibrosis.
|
23237012 |
2013 |
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study confirms the concept of RGT in HIV/HCV coinfection and supports the extension of therapy duration to 72 weeks for patients with GT1/4-noRVR, especially in patients with IL28B non-C/C or advanced liver fibrosis.
|
23835502 |
2013 |